Intriguingly, the AUCs of SOX2OT and ANRIL were both greater than those of the currently used tumor markers (CEA, CYFRA21‐1, and SCCA), indicating remarkable efficacy of SOX2OT and ANRIL in distinguishing NSCLC patients from controls. This evidence concerns the gene CEACAM5 and non-small cell lung carcinoma.